Aspire Biopharma (ASBP) said Wednesday it expects to launch Buzz Bomb, its sublingual pre-workout supplement, in Q3.
The company has started initial production of the new supplement, which features 50mg of caffeine and is designed to support "sustained energy and mental focus."
Aspire Biopharma shares were 72% higher in premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.